Professional societies have published testing recommendations limited to specific genes such as BRCA1/2 and those associated with well-described hereditary cancer conditions such as Li-Fraumeni (TP53) and Cowden syndrome (PTEN).3,5. This evidence concerns the gene PTEN and hereditary cancer.